BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37649596)

  • 21. CD163+ tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients.
    Yang L; Wang F; Wang L; Huang L; Wang J; Zhang B; Zhang Y
    Oncotarget; 2015 Apr; 6(12):10592-603. PubMed ID: 25871392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies.
    Liu X; Lu Y; Zhu G; Lei Y; Zheng L; Qin H; Tang C; Ellison G; McCormack R; Ji Q
    J Clin Pathol; 2013 Dec; 66(12):1065-9. PubMed ID: 23888061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C1q
    Zhang S; Peng W; Wang H; Xiang X; Ye L; Wei X; Wang Z; Xue Q; Chen L; Su Y; Zhou Q
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37604643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
    Tsai TH; Su KY; Wu SG; Chang YL; Luo SC; Jan IS; Yu CJ; Yu SL; Shih JY; Yang PC
    Eur Respir J; 2012 Mar; 39(3):677-84. PubMed ID: 21719485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deconvolution of malignant pleural effusions immune landscape unravels a novel macrophage signature associated with worse clinical outcome in lung adenocarcinoma patients.
    Bruschini S; Pallocca M; Sperandio E; D'Ambrosio L; Ascenzi F; De Vitis C; Salvati V; Esposito A; Di Martino S; De Nicola F; Paolini F; Fattore L; Alessandrini G; Facciolo F; Foddai ML; Bassi M; Venuta F; D'Ascanio M; Ricci A; D' Andrilli A; Napoli C; Aurisicchio L; Fanciulli M; Rendina EA; Ciliberto G; Mancini R
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35584864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Results of EGFR Mutations Detected in Pleural Effusion and Its 
Clinical Significance in 132 Patients with Advanced Non-small Cell Lung Cancer: 
A Retrospective Study in A Single Center].
    Lu T; Li Q; Li L; Yang K; Zhou D; Gao J; Chen M; Xu Y; Zhong W; Wang M; Liang Z; Zhao J
    Zhongguo Fei Ai Za Zhi; 2020 Dec; 23(12):1059-1065. PubMed ID: 33357312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors.
    Yang J; Lee OJ; Son SM; Woo CG; Jeong Y; Yang Y; Kwon J; Lee KH; Han HS
    Cancer Res Treat; 2018 Jul; 50(3):908-916. PubMed ID: 28934846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma.
    Verma A; Chopra A; Lee YW; Bharwani LD; Asmat AB; Aneez DB; Akbar FA; Lim AY; Chotirmall SH; Abisheganaden J
    Curr Drug Discov Technol; 2016; 13(2):68-76. PubMed ID: 27216707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved detection of EGFR mutations in the tumor cells enriched from the malignant pleural effusion of non-small cell lung cancer patient.
    Wang Y; Liu Z; Yin H; Hu J; Zhong S; Chen W; Zhao J
    Gene; 2018 Feb; 644():87-92. PubMed ID: 29097164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.
    Zeng XY; Xie H; Yuan J; Jiang XY; Yong JH; Zeng D; Dou YY; Xiao SS
    Cancer Biol Ther; 2019; 20(7):956-966. PubMed ID: 31062668
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinicopathological significance of microRNA-21 in extracellular vesicles of pleural lavage fluid of lung adenocarcinoma and its functions inducing the mesothelial to mesenchymal transition.
    Watabe S; Kikuchi Y; Morita S; Komura D; Numakura S; Kumagai-Togashi A; Watanabe M; Matsutani N; Kawamura M; Yasuda M; Uozaki H
    Cancer Med; 2020 Apr; 9(8):2879-2890. PubMed ID: 32091667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples.
    Yao Y; Peng M; Shen Q; Hu Q; Gong H; Li Q; Zheng Z; Xu B; Li Y; Dong Y
    Thorac Cancer; 2019 Feb; 10(2):193-202. PubMed ID: 30565433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-cell analysis of diverse immune phenotypes in malignant pleural effusion.
    Huang ZY; Shao MM; Zhang JC; Yi FS; Du J; Zhou Q; Wu FY; Li S; Li W; Huang XZ; Zhai K; Shi HZ
    Nat Commun; 2021 Nov; 12(1):6690. PubMed ID: 34795282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
    Guo H; Wan Y; Tian G; Liu Q; Kang Y; Li Y; Yao Z; Lin D
    Oncol Rep; 2012 Mar; 27(3):880-90. PubMed ID: 22134479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation.
    Zou J; Bella AE; Chen Z; Han X; Su C; Lei Y; Luo H
    J Int Med Res; 2014 Oct; 42(5):1110-7. PubMed ID: 25239875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-Cell RNA Sequencing Reveals the Heterogeneity of Tumor-Associated Macrophage in Non-Small Cell Lung Cancer and Differences Between Sexes.
    Yang Q; Zhang H; Wei T; Lin A; Sun Y; Luo P; Zhang J
    Front Immunol; 2021; 12():756722. PubMed ID: 34804043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay.
    Wang MC; Wang CL; Chen TL; Chang JW; Lu JJ; Chang PY; Chiou CC
    Clin Chem Lab Med; 2017 Oct; 55(12):1979-1986. PubMed ID: 28787267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leveraging Bulk and Single-Cell RNA Sequencing Data of NSCLC Tumor Microenvironment and Therapeutic Potential of NLOC-15A, A Novel Multi-Target Small Molecule.
    Lawal B; Wu ATH; Huang HS
    Front Immunol; 2022; 13():872470. PubMed ID: 35655775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of the alternative splicing landscape in lung adenocarcinoma reveals novel prognosis signature associated with B cells.
    Shao MM; Zhai K; Huang ZY; Yi FS; Zheng SC; Liu YL; Qiao X; Chen QY; Wang Z; Shi HZ
    PLoS One; 2023; 18(7):e0279018. PubMed ID: 37432957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
    Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
    Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.